{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shehata MM"],"funding":["Academy of Scientific Research and Technology","Imam Abdulrahman Bin Faisal University"],"pagination":["6182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8540548"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(20)"],"pubmed_abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the causative agent of coronavirus disease (COVID-19)) has caused relatively high mortality rates in humans throughout the world since its first detection in late December 2019, leading to the most devastating pandemic of the current century. Consequently, SARS-CoV-2 therapeutic interventions have received high priority from public health authorities. Despite increased COVID-19 infections, a vaccine or therapy to cover all the population is not yet available. Herein, immunoinformatics and custommune tools were used to identify B and T-cells epitopes from the available SARS-CoV-2 sequences spike (S) protein. In the in silico predictions, six B cell epitopes QTGKIADYNYK, TEIYQASTPCNGVEG, LQSYGFQPT, IRGDEVRQIAPGQTGKIADYNYKLPD, FSQIL"],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine."],"pmcid":["PMC8540548"],"funding_grant_id":["(7182), Ideation Fund program","Covid19-2020-001-BASRC"],"pubmed_authors":["M Elhefnawi M","Mahmoud A","Mostafa A","Shehata MM","Ali MA","Al-Karmalawy AA","Mahmoud SH","Tarek M"],"additional_accession":[]},"is_claimable":false,"name":"In Silico and In Vivo Evaluation of SARS-CoV-2 Predicted Epitopes-Based Candidate Vaccine.","description":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, the causative agent of coronavirus disease (COVID-19)) has caused relatively high mortality rates in humans throughout the world since its first detection in late December 2019, leading to the most devastating pandemic of the current century. Consequently, SARS-CoV-2 therapeutic interventions have received high priority from public health authorities. Despite increased COVID-19 infections, a vaccine or therapy to cover all the population is not yet available. Herein, immunoinformatics and custommune tools were used to identify B and T-cells epitopes from the available SARS-CoV-2 sequences spike (S) protein. In the in silico predictions, six B cell epitopes QTGKIADYNYK, TEIYQASTPCNGVEG, LQSYGFQPT, IRGDEVRQIAPGQTGKIADYNYKLPD, FSQIL","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-05T12:56:25.213Z","creation":"2025-04-05T12:56:25.213Z"},"accession":"S-EPMC8540548","cross_references":{"pubmed":["34684763"],"doi":["10.3390/molecules26206182"]}}